Cantor Fitzgerald set a $162.00 price target on Celgene Corporation (NASDAQ:CELG) in a research note issued to investors on Thursday, October 26th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently weighed in on CELG. Guggenheim began coverage on Celgene Corporation in a research report on Monday, October 23rd. They issued a buy rating and a $160.00 target price for the company. Morgan Stanley cut their target price on Celgene Corporation from $120.00 to $115.00 and set an underweight rating for the company in a research report on Monday, October 23rd. Piper Jaffray Companies restated a neutral rating and issued a $133.00 target price on shares of Celgene Corporation in a research report on Monday, October 23rd. Vetr upgraded Celgene Corporation from a buy rating to a strong-buy rating and set a $144.39 target price for the company in a research report on Monday, October 23rd. Finally, BTIG Research reaffirmed a hold rating on shares of Celgene Corporation in a report on Sunday, October 22nd. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $139.64.
Celgene Corporation (CELG) opened at $98.86 on Thursday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $77,830.00, a P/E ratio of 15.81, a price-to-earnings-growth ratio of 0.78 and a beta of 1.79. Celgene Corporation has a 52 week low of $94.55 and a 52 week high of $147.17.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.58 earnings per share. equities research analysts predict that Celgene Corporation will post 6.67 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/celgene-corporation-celg-given-a-162-00-price-target-by-cantor-fitzgerald-analysts-2/1738906.html.
In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders have sold 20,227 shares of company stock valued at $2,843,956 in the last ninety days. 0.95% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the stock. Thompson Davis & CO. Inc. raised its position in Celgene Corporation by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI increased its holdings in shares of Celgene Corporation by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares in the last quarter. Robecosam AG acquired a new stake in shares of Celgene Corporation during the third quarter worth approximately $114,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Celgene Corporation during the first quarter worth approximately $118,000. Finally, Guidant Wealth Advisors acquired a new stake in shares of Celgene Corporation during the third quarter worth approximately $119,000. 79.16% of the stock is owned by hedge funds and other institutional investors.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.